

## ETHIOPIA Support for Measles Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

- 1. Country: Ethiopia
- 2. Grant number: 1820-ETH-09b-X / 18-ETH-08n-Y
- 3. Date of Decision Letter: 18 December 2017
- 4. Date of the Partnership Framework Agreement: 23 july 2013
- **5. Programme title:** New Vaccine Support (NVS), Measles first and second dose (two dose schedule) Routine
- 6. Vaccine type: Measles
- Requested product presentation and formulation of vaccine: Measles, 10 dose(s) per vial, LYOPHILISED
- 8. Programme duration<sup>1</sup>: 2018 2020
- **9. Programme Budget (indicative):** (subject to the terms of the partnership framework agreement, if applicable)

	2018	2019	2020	Total <sup>2</sup>
Programme Budget (US\$)	US\$714,500	US\$608,500	US\$631,500	US\$1,954,500

10. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)<sup>3</sup>

Type of supplies to be purchased with Gavi funds in each year (Routine)	2018
Number of Measles vaccines doses	2,416,000
Annual Amounts (US\$)	US\$714,500

<sup>3</sup> This is the amount that Gavi has approved.

2 Chemin des Mines 1202 Geneva. Switzerland Tel. + 41 22 909 65 00 Fax + 41 22 909 65 50 www.gavi.org info@gavi.org

<sup>&</sup>lt;sup>1</sup> This is the entire duration of the Programme.

<sup>&</sup>lt;sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.



- **11. Procurement agency:** UNICEF. The Country shall release its co-financing payments each year to UNICEF.
- 12. Self-procurement: Not applicable
- 13. Co-financing obligations for routine: Reference code: 1820-ETH-09b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2018	2019	2020
Number of vaccine doses	5,048,400	4,298,900	4,459,800
Value of vaccine doses (US\$)	US\$1,363,064	US\$1,160,695	US\$1,204,121
Total co-financing payments (US\$) (including freight)	US\$1,493,000	US\$1,271,500	US\$1,319,000
Minimum number of doses to be financed from domestic resources	4,976,267	4,237,467	4,396,067
Minimum amount to be financed from domestic resources (US\$)	US\$ 1,343,592	US\$ 1,144,116	US\$ 1,186,938

- 14. Co-financing obligations for campaign: Not Applicable
- **15. Vaccine introduction grant (in US\$):** 2,672,270. Payable up to six months before vaccine introduction.
- 16. Operational support for campaigns: Not applicable



## 17. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts: Not applicable

Reports and other information	Due dates	
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May 2018	
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat	

18. Financial clarifications: Not applicable

19. Other conditions: Not applicable

Signed by,

On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

While St. Inality

18 December 2017